Last updated on January 2019

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old With Hodgkin's Lymphoma (cHL) Relapsed or Refractory From First Line Treatment

Brief description of study

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Clinical Study Identifier: NCT02927769

Contact Investigators or Research Sites near you

Start Over

Local Institution

Fairfax, VA United States
  Connect »

Children'S National Medical Center

Washington, WA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.